Publications and Presentations

Filter By:

Ipatasertib

07/18/2012

Organic Reactions and Processes, Gordon Research Conference

Route Scouting and Early Process Development of a Challenging Cyclopentylpyrimidine Intermediate in ARRY-452/GDC-0068

J. Lane, et al.

ARRY-797

07/05/2012

Human Molecular Genetics

Abnormal p38 mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation

A. Muchir, et al.

ARRY-614

06/16/2012

European Hematology Association Annual Congress

Clinical Evaluation of ARRY-614, a Dual p38/Tie2 Inhibitor for Patients with Myelodysplastic Syndromes, Identifies Unique Disease-Related and Drug-Related Biomarkers

G. Garcia-Manero, et al.

Binimetinib

06/04/2012

American Society of Clinical Oncology Annual Meeting

Efficacy and Safety of Oral MEK162 in Patients with Locally Advanced and Unresectable or Metastatic Cutaneousmelanoma Harboring BRAFV600 or NRAS Mutations

P. A. Ascierto, et al.

Filanesib

06/04/2012

Cambridge Healthtech Institute Conference

The Discovery and Optimization of Kinesin Spindle Protein (KSP) Inhibitors: Path to ARRY-520

S. Allen, et al.

Ipatasertib

06/04/2012

American Society of Clinical Oncology Annual Meeting

A Phase Ib/II Study Testing the Safety and Efficacy of Combined Inhibition of the PI3K/Akt and Androgen Receptor Signaling Pathways in Castration-resistant Prostate Cancer: GDC-0068 or GDC-0980 with Abiraterone Acetate Versus Abiraterone Acetate

R. Funke, et al.

Selumetinib

06/04/2012

American Society of Clinical Oncology Annual Meeting

Reacquisition of RAI incorporation of RAIĀ]refractory metastatic thyroid cancers by pretreatment with the selective MEK inhibitor Selumetinib (AZD6244): A pilot study (NCT00970359)

A. L. Ho, et al.

Ipatasertib

06/02/2012

American Society of Clinical Oncology Annual Meeting

A Phase Ib Study of the Akt Inhibitor GDC-0068 with Docetaxel or mFOLFOX6 in Patients with Advanced Solid Tumors

C. Saura, et al.

Selumetinib

04/02/2012

American Association for Cancer Research Annual Meeting

A PHASE II TRIAL OF SELUMETINIB (AZD6244; ARRY-142886)

J. Farley, et al.

Filanesib

04/02/2012

American Association for Cancer Research Annual Meeting

Human Tumor Explants are Better Predictors of Clinical Trial Outcome than Solid Tumor Cell Line Xenografts for the KSP Inhibitor ARRY-520

M. J. Humphries, et al.